Modern approach in cancer immunotherapy
Vol 82 No 1 (2019), Theoretical and Experimental Medicine
Vol 82 No 1 (2019)

Modern approach in cancer immunotherapy

Theoretical and Experimental Medicine
https://doi.org/10.35339/ekm.2019.01.02
Published July 1, 2020
A.Yu. Gavrilov
Kharkov National Medical University
https://orcid.org/0000-0001-8644-6887
І.А. Sennikov
Kharkov National Medical University
https://orcid.org/0000-0002-5690-2703
V.V. Lesnoy
Kharkov National Medical University
https://orcid.org/0000-0001-8257-2130
A.S. Lesnаy
Kharkov National Medical University
https://orcid.org/0000-0002-6045-1650
V.V. Poliakova
Kharkov National Medical University
https://orcid.org/0000-0001-8570-5584
PDF (Русский)

Keywords

oncolytic viruses
cancer immunotherapy

How to Cite

Gavrilov, A., SennikovІ., Lesnoy, V., LesnаyA., & Poliakova, V. (2020). Modern approach in cancer immunotherapy. Experimental and Clinical Medicine, 82(1), 9-16. https://doi.org/10.35339/ekm.2019.01.02
ACM ACS APA ABNT Chicago Harvard IEEE MLA Turabian Vancouver

Download Citation

Endnote/Zotero/Mendeley (RIS) BibTeX

Abstract

The paper discusses the main directions and results of experimental and clinical studies of cancer immunotherapy. The prospects for the use and realization of the oncolytic potential of viruses are discussed. The results of our own research and analysis of literary data made it possible to comprehensively approach the assessment of the possibility of using oncolytic viruses in the treatment of patients with cancer.
https://doi.org/10.35339/ekm.2019.01.02
PDF (Русский)

References

Rak v Ukraini [Cancer in Ukraine] (2018). Biuleten Natsionalnoho kantser-reiestru – Bulletin of the National Chancery Register. № 20, Kyiv, 118 p. [in Ukrainian].

Lundstrom K. Latest trends in cancer therapy applying viral vectors. (2017). Future Virol., vol. 212, pp. 667–684.

Lin Y., Zhang H., Liang J. et al. (2016). Identification and characterization of alphavirus M1 as a selective oncolytic virus targeting ZAP-defective human cancers. Proc. Natl. AcadSci. USA, vol. 11, рр. 4504–4512.

Lin E., Nemunaitis J. Oncolytic viral therapies. (2016). Cancer Gene. Ther., vol. 11, рр. 643–664.

Kaufman H.L., Kohlhapp F.J., Zloza A. (2015). Oncolytic viruses: a new class of immunotherapy drugs. Nat. Rev. Drug Discov., vol. 14, рр. 642–662.

Verheije M.H., Rottier P.J. (2017). Retargeting of viruses to generate oncolytic agents. Adv. Virol., vol. 20, рр. 313–329.

Marelli G., Sica A., Vannucci L., Allavena P. (2017). Inflammation as target in cancer therapy. Curr. Opin. Pharmacol., vol. 14, рр. 35–37.

Russell S.J., Federspiel M.J., Peng K.W. [et al.] (2014). Remission of disseminated cancer after systemic oncolytic virotherapy. Mayo Clin. Proc., vol. 89, рр. 926–932.

Ilett E., Kottke T., Donnelly O. et al. (2014). Cytokine conditioning enhances systemic delivery and therapy of an oncolytic virus. Mol. Ther., vol. 22, рр. 1851–1858.

Goldufsky J. (2013). Oncolytic virus therapy for cancer. Oncolytic. Virother., vol. 2, рр. 31–46.

Larocca C, Schlom J. (2011). Viral Vector–based Therapeutic Cancer Vaccines. Cancer J., vol. 17, рр. 359–369.

Martin N.T., Bell J.C. (2018). Oncolytic virus combination therapy: Killing one bird with two stones. Mol. Ther., vol. 26, рр. 1414–1422.